The attitudes of Australian gynaecologists to HPV vaccination: An ASCCP survey

Australian and New Zealand Journal of Obstetrics and Gynaecology

Volumn 50, Issue 5, 2010, Pages 472-477

  Tan, Jeffrey ^a   Farrell, Louise ^b   Allen, David G ^c  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b ST JOHN OF GOD HOSPITAL   (Australia)

^c Mercy Hospital   (Australia)

Author keywords

Attitude; Human papilloma virus vaccines; Internet; Knowledge; Surveys

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; ATTITUDE; AUSTRALIA; CHILD; COLPOSCOPY; FEMALE; HEALTH SURVEY; HUMAN; INTERNET; KNOWLEDGE; MALE; MEDICAL SPECIALIST; MEDICAL STUDENT; NEW ZEALAND; PRIORITY JOURNAL; SCHOOL CHILD; VACCINATION; WART VIRUS;

ADOLESCENT; ADULT; AGE FACTORS; ATTITUDE OF HEALTH PERSONNEL; AUSTRALIA; CHILD; FEMALE; GYNECOLOGY; HEALTH SURVEYS; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINATION; YOUNG ADULT;

EID: 78650225869     PISSN: 00048666     EISSN: 1479828X     Source Type: Journal    
DOI: 10.1111/j.1479-828X.2010.01205.x     Document Type: Article

References (11)

1. Pitts MK, Dyson SJ, Rosenthal DA, Garland SM. Knowledge and awareness of human papillomavirus (HPV): attitudes towards HPV vaccination among a representative sample of women in Victoria, Australia. Sex Health 2007;4(3):177-180.
2. Rosethal D, Dyson S, Pitts M, Garland S. Challenges to accepting a human papilloma virus (HPV) vaccine: a qualitative study of Australian women. Women Health 2007;45(2):59-73.
3. Duval B, Gilca V, McNeil S et al. Vaccination against human papillomavirus: a baseline survey of Canadian clinicians' knowledge, attitudes and beliefs. Vaccine 2007;25:7841-7847.
4. Daley MF, Liddon N, Crane LA et al. A national survey of pediatrician knowledge and attitudes regarding human papillomavirus vaccination. Pediatrics 2006;118:2280-2289.
5. de Carvalho NS, Teixeira LM, Pradel EM, Gabardo J, Joly C, Urbanetz AA. Vaccinating against HPV: physicians' and medical students' point of view. Vaccine 2009;27:2637-2640.
6. David MP, Van Herck K, Hardt K et al. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol 2009;115(Suppl 3): S1-S6. Epub 2009 Feb. 12.
7. Kulasingam S, Connelly L, Conway E et al. A costeffectiveness analysis of adding a human papillomavirus vaccine to the Australian National Cervical Cancer Screening Program. Sex Health 2007;4(3):165-175.
8. Skinner R, Verheijen R, Martens M et al. Estimating prior HPV16/18 exposure by age group of women enrolled in Phase III clinical trials of GSK's HPV vaccine. [Abstract]. EUROGIN 2007; SS1-1 p 40.
9. Castle PE, Schiffman M, Herrero R et al. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 2005;191:1808-1816.
10. Schwarz TF, Spaczynski M, Schneider A et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009;27:581-587.
11. Munoz N, Manalastas R Jr, Pitisuttithum P et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009;373:1949-1957.